Cellectis S.A. American Depositary Shares (CLLS) Stock Price

CLLSStock

$3.42+19.83%52W

Market Cap$344.40M

P/E—

PEG Ratio—

Div yield—

Beta0.85

CLLS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.19%

Price vs S&P 500 (4W)6.57%

VGM Score55.67

P/CF (Annual)10.79x

Book Value / Share (Quarterly)$0.83

P/TBV (Annual)4.59x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.72%

Cash Flow / Share (Quarterly)$-0.81

Price vs S&P 500 (YTD)-44.90%

Gross Margin (TTM)34.83%

Net Profit Margin (TTM)-68.19%

EPS (TTM)$-0.85

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-0.85

Revenue Growth (5Y)5.97%

EPS (Annual)$-0.67

ROI (Annual)-36.47%

Gross Margin (Annual)43.61%

Net Profit Margin (5Y Avg)-393.48%

Cash / Share (Quarterly)$2.57

Revenue Growth QoQ (YoY)-37.25%

ROA (Last FY)-20.82%

Revenue Growth TTM (YoY)56.76%

EBITD / Share (TTM)$-0.34

ROE (5Y Avg)-75.60%

Operating Margin (TTM)-40.39%

Cash Flow / Share (Annual)$-0.59

P/B Ratio3.70x

P/B Ratio (Quarterly)3.94x

Net Income / Employee (Annual)$-295,200

EV / Revenue (TTM)2.31x

Net Interest Coverage (TTM)-0.95x

ROA (TTM)-25.87%

EPS Incl Extra (Annual)$-0.67

Current Ratio (Annual)1.62x

Quick Ratio (Quarterly)1.49x

3-Month Avg Trading Volume0.21M

52-Week Price Return19.83%

EV / Free Cash Flow (Annual)8.19x

Revenue / Employee (TTM)$542,800

Tangible BV / Share (Quarterly)$0.83

P/S Ratio (Annual)2.79x

Asset Turnover (Annual)0.25x

52-Week High$4.84

Operating Margin (5Y Avg)-367.53%

EPS Excl Extra (Annual)$-0.67

CapEx CAGR (5Y)-41.81%

Tangible BV CAGR (5Y)-22.75%

26-Week Price Return-18.94%

Quick Ratio (Annual)1.61x

13-Week Price Return-13.88%

Total Debt / Equity (Annual)1.44x

Current Ratio (Quarterly)1.52x

Enterprise Value$286.81M

Revenue / Share Growth (5Y)-10.75%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)-30.44%

Revenue / Employee (Annual)$347,600

Inventory Turnover (Annual)82.27x

Pretax Margin (Annual)-85.46%

Cash / Share (Annual)$2.88

3-Month Return Std Dev56.46%

Gross Margin (5Y Avg)-84.99%

Net Income / Employee (TTM)$-370,200

ROE (Last FY)-89.05%

Net Interest Coverage (Annual)-0.85x

EPS Basic Excl Extra (Annual)$-0.67

P/FCF (TTM)4.52x

Receivables Turnover (TTM)19.09x

Total Debt / Equity (Quarterly)1.66x

EPS Incl Extra (TTM)$-0.85

Receivables Turnover (Annual)7.54x

ROI (TTM)-45.87%

P/S Ratio (TTM)1.79x

Pretax Margin (5Y Avg)-412.20%

Revenue / Share (Annual)$0.79

Tangible BV / Share (Annual)$1.04

Price vs S&P 500 (52W)1.52%

Year-to-Date Return-34.30%

5-Day Price Return4.00%

EPS Normalized (Annual)$-0.67

ROA (5Y Avg)-26.23%

Net Profit Margin (Annual)-84.92%

Month-to-Date Return11.67%

Cash Flow / Share (TTM)$-0.66

EBITD / Share (Annual)$-0.13

Operating Margin (Annual)-41.56%

LT Debt / Equity (Annual)0.98x

ROI (5Y Avg)-39.44%

LT Debt / Equity (Quarterly)1.13x

EPS Basic Excl Extra (TTM)$-0.85

P/TBV (Quarterly)3.95x

P/B Ratio (Annual)4.56x

Inventory Turnover (TTM)93.83x

Pretax Margin (TTM)-68.50%

Book Value / Share (Annual)$1.05

Price vs S&P 500 (13W)-16.67%

Beta0.85x

P/FCF (Annual)11.59x

Revenue / Share (TTM)$1.24

ROE (TTM)-101.70%

52-Week Low$2.03

vGradeB

gGradeC

mGradeC

vgmGradeC

CLLS Earnings Surprise History

Q2 25-0.22est. -0.15

Q3 250.02est. -0.10

Q4 25-0.24est. -0.10

Q1 26-0.18est. -0.26

Q2 26-0.22est. -0.25

CLLS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.23

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CLLSCellectis S.A. American Depositary Shares	B	C	C	$3.42
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Cellectis S.A. American Depositary Shares

Cellectis SA is a clinical-stage biotechnology company developing gene-editing treatments for cancer and other diseases. The company's pipeline includes allogeneic CAR-T cell therapies for immuno-oncology and gene-edited stem cell products for other therapeutic areas. Its proprietary technology platform creates off-the-shelf cellular therapies with the potential for improved clinical outcomes and broader patient access.